Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver

Table 1 Baseline characteristics of the study population

Characteristic	Males	Females	Total
Sex	8	21	29
Race
Caucasian	7	16	23
African American	1	4	5
Other/unknown	0	1	1
Presence of
Diabetes	3	15	18
Hypertension	8	17	25
Obesity	5	10	15
Reason for PCSK-9 inhibitor initiation
Statin intolerance	4	16	20
Inadequate lipid control	2	4	6
Not known	2	1	3

PCSK9: Proprotein convertase subtilisin/kexin type-9.

Table 2 Types of proprotein convertase subtilisin/kexin type-9 inhibitor used by the study population

	Males	Females	Total
Type of PCSK9 inhibitor
Evolocumab	5	17	22
Alirocumab	3	4	7
Age in year at PCSK9 inhibitor initiation, mean ± SD	67.7 ± 7.6	63.6 ± 9.6	64.8 ± 9.1
Concomitant statin therapy during PCSK-9 therapy	1	5	6

PCSK9: Proprotein convertase subtilisin/kexin type-9; SD: Standard deviation.

Table 3 Effects of proprotein convertase subtilisin/kexin type-9 inhibitor on secondary outcome (alanine aminotransferase and aspartate aminotransferase) and lipid panel

Parameter	Males	Females	Combined
Time elapsed in month from PCSK9 inhibitor initiation until most recent ALT and AST measurements	18.4 ± 11.2	25.71 ± 10.74	23.69 ± 11.18
	Pre-treatment	Post-treatment	Sig (2-tailed)1
ALT in IU/L	21.83 ± 11.89	17.69 ± 8.00	0.042
AST in IU/L	22.48 ± 9.00	20.59 ± 5.47	0.201
LDL in mg/dL	150.43 ± 44.69	90.89 ± 35.67	0.000
Triglycerides in mg/dL	220.07 ± 143.36	196.34 ± 140.73	0.447
HDL in mg/dL	48.59 ± 12.97	48.90 ± 16.27	0.884

Data are presented as mean ± standard deviation.

¹2-tailed P value for paired t-test. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; PCSK9: Proprotein convertase subtilisin/kexin type-9.